[1] |
祝爽爽, 王林, 江启锋, 等. 成人节段性膜性肾病1例. 实用医学杂志,2019,2: 337–338. doi: 10.3969/j.issn.1006-5725.2019.02.040
|
[2] |
BECK L H, Jr, BONEGIO R G, LAMBEAU G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med,2009,361(1): 11–21. doi: 10.1056/NEJMoa0810457
|
[3] |
REN S, WU C, ZHANG Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail,2018,40(1): 306–313. doi: 10.1080/0886022X.2018.1456457
|
[4] |
SETHI S, DEBIEC H, MADDEN B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int,2020,97(1): 163–174. doi: 10.1016/j.kint.2019.09.014
|
[5] |
SETHI S, DEBIEC H, MADDEN B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int,2020,98(5): 1253–1264. doi: 10.1016/j.kint.2020.05.030
|
[6] |
FOGO A B, LUSCO M A, NAJAFIAN B, et al. AJKD Atlas of renal pathology: membranous nephropathy. Am J Kidney Dis,2015,66(3): e15–17. doi: 10.1053/j.ajkd.2015.07.006
|
[7] |
DUCROT H, TSOMI C, JUNGERS P, et al. Anatomoclinical study of extramembraneous glomerulonephritis. J Urol Nephrol (Paris),1969,75(9): 636–642.
|
[8] |
KUDOSE S, SANTORIELLO D, DEBIEC H, et al. The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney Int,2021,99(1): 247–255. doi: 10.1016/j.kint.2020.06.014
|
[9] |
KIM Y, BUTKOWSKI R, BURKE B, et al. Differential expression of basement membrane collagen in membranous nephropathy. Am J Pathol,1991,139(6): 1381–1388.
|
[10] |
YAMAMOTO S, INABA S, YOSHIDA R, et al. Clinicopathological characteristics of the focal and segmental form of idiopathic membranous nephropathy: comparison with the typical form of this disease. Acta Paediatr Jpn,1997,39(3): 349–353. doi: 10.1111/j.1442-200x.1997.tb03751.x
|
[11] |
CAZA T N, HASSEN S I, DVANAJSCAK Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int,2021,99(4): 967–976. doi: 10.1016/j.kint.2020.07.039
|
[12] |
SEGAWA Y, HISANO S, MATSUSHITA M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol,2010,25(6): 1091–1099. doi: 10.1007/s00467-009-1439-8
|
[13] |
LARSEN C P, TRIVIN C, COLES P, et al. LDL receptor-related protein 2 (Megalin) as a target antigen in human kidney anti-brush border antibody disease. J Am Soc Nephrol,2018,29(2): 644–653. doi: 10.1681/ASN.2017060664
|
[14] |
JENNETTE J, ISKANDAR S, DALLDORF F. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int,1983,24(3): 377–385. doi: 10.1038/ki.1983.170
|
[15] |
ALEXANDER M P, LARSEN C P, GIBSON I W, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int,2013,83(3): 455–462. doi: 10.1038/ki.2012.382
|
[16] |
LARSEN C P, MESSIAS N C, SILVA F G, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol,2013,26(5): 709–715. doi: 10.1038/modpathol.2012.207
|
[17] |
CHOUNG H Y G, GOLDMAN B. Segmental membranous nephropathy. Clin Exp Nephrol,2021,25(7): 700–707. doi: 10.1007/s10157-021-02056-1
|